Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (379)	1/6/1999 12:25:00 AM
From: scaram(o)uche	Respond to of 4974

Stuart: That helps give a nice picture of the company. Looks like the "whole blood" patent is likely a separate Cytomed, but all of the others are relevant. I once interviewed, ages ago, at Merck. They wined and dined me, and offered me a slot if I would agree to work on Leukotrienes for my "hobby" project. I refused, and subsequently went to Bayer. Merck has been grinding on leukotrienes ever since, and CytoMed isn't exactly alone in the area. This sort of home-foot-work helps a number of people assess their companies or potential investments. The claims are largely chemistry, so it doesn't mean much to me. However, we know that they have compounds with oral activity and that the projects have been ongoing for quite some time. Now, if you choose to extend this sort of extremely helpful work, this is what I normally do next...... I make a list of the inventors, in the format of Smith RJ (for Rebecca J. Smith). I then go to Medline (PubMed), and plug the authors' names into the search field to see if I can turn up abstracts from publications. The abstracts from manuscripts ALWAYS give more insight than the BS in the patent abstracts, and you can also get a concept of how prolific the inventor was before he went into industry. You can learn tons about a company by this route. You'll often also hit dry wells. Nobody knows more about the role of chemokines, leukosite migration and cellular adhesion in inflammation than LKST. This merger looks like a decent fit. ***** THANKS ****** Rick

To: sim1 who wrote (379)	1/10/1999 11:08:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Stuart: And, if you search using the inventor's names as I discussed, you turn up stuff like this....... J Med Chem 1998 May 21;41(11):1970-9 (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. Cai X, Scannell RT, Yaeger D, Hussoin MS, Killian DB, Qian C, Eckman J, Hwang SB, Libertine-Garahan L, Yeh CG, Ip SH, Shen TY CytoMed, Inc., 840 Memorial Drive, Cambridge, Massachusetts 02139, and Department of Chemistry, University of Virginia, Charlottesville, Virginia 22903, USA. By incorporating an N-hydroxyurea functionality onto diaryltetrahydrofurans, a novel series of compounds was investigated as dual 5-lipoxygenese (5-LO) inhibitor and platelet-activating factor (PAF) receptor antagonist. These dual functional compounds were evaluated in vitro for 5-LO inhibition in RBL cell extracts and human whole blood, and PAF receptor antagonism in a receptor binding assay. PAF-induced hemoconcentration and arachidonic acid- and TPA-induced ear edema in mice were used to determine in vivo activities. The structure-activity relationship analysis to define a preclinical lead is presented. (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl- N-h ydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (40, CMI-392) was selected for further study. In the arachidonic acid-induced mouse ear edema model, 40 was more potent than either zileuton (a 5-LO inhibitor) or BN 50739 (a PAF receptor antagonist), and it demonstrated the same inhibitory effect as a physical combination of the latter two agents. These results suggest that a single compound which both inhibits leukotriene synthesis and blocks PAF receptor binding may provide therapeutic advantages over single-acting agents. The clinical development of compound 40 is in progress. ************* at which time, if you're a LKST shareholder, you start to take serious interest. Thanks again, Rick

To: sim1 who wrote (379)	1/10/1999 11:46:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

getting clearer....... these guys were very proactive in getting together with a partner in inflammation, to position themselves lean and mean going forward....... CytoMed Enters Into Agreement with UCB Pharma -- License and Technology Asset Purchase to Provide up to $18 Million -- Cambridge, MA, October 26, 1998 – CytoMed, Inc. announced today that the Company has entered into a license and technology asset purchase agreement with UCB Pharma of Brussels, Belgium. UCB Pharma has acquired rights to the allergy applications of CytoMed's novel anti-inflammatory dual function inhibitor compounds and pre-development research programs. CytoMed will commit its resources to the strategic development of its current product portfolio, which includes: CMI-977, an oral leukotriene modulator in Phase I trials for the treatment of asthma; CMI-392, a topical product in Phase II trials for the treatment of chronic inflammatory skin disorders; and CMI-CAB-2, an injectable complement inhibitor in preclinical studies for the treatment of acute pulmonary inflammation. The transaction with UCB Pharma provides for payments totaling $12 million for the acquisition of CytoMed's research and discovery assets and has the potential to provide up to $6 million in product development and milestone fees. UCB Pharma will also assume certain ongoing activities associated with the research and discovery component of CytoMed and its facilities costs. "CytoMed's expertise in pharmacological and medicinal chemistry has led to the discovery of important new therapies for a wide range of allergy-related diseases," said Edouard P. Croufer, Director General, UCB-Pharma Sector. "The acquisition of CytoMed's drug discovery and research programs reflects our strategy to expand UCB Pharma's scientific presence in the United States and to acquire exclusive rights to promising new technologies." "We have created an exciting portfolio of product candidates for the treatment of key inflammatory disorders," said Frederick Kyle, Chairman of CytoMed. "The recent agreement with UCB provides CytoMed with significant additional funding that enhances our ability to advance our lead compounds through clinical trials toward commercialization. We also plan to continue to maintain CytoMed's strategic focus on anti-inflammation product development and its lean infrastructure." "CytoMed has developed a promising product pipeline based on an advanced understanding of key inflammatory response pathways," said Richard Woodrich, Executive Vice President of CytoMed. "This agreement with UCB is a recognition of our ability to design compounds that selectively modulate specific events within these pathways, potentially providing better drugs that safely and effectively mitigate the adverse effects of inflammation. We now look forward to focusing our corporate resources and development expertise on our own relatively near-term product opportunities." Under terms of the agreement, UCB Pharma has offered employment to approximately 35 research scientists and laboratory personnel. Thomas Beck, M.D., who served as CytoMed's President and CEO prior to the transaction, has also been offered a position in UCB Pharma's senior management. CytoMed will retain a staff of approximately 15 people to oversee the clinical development of its product portfolio. UCB Pharma is an international leader in pharmaceutical research, manufacturing, and marketing. The Company's research is focused on the central nervous system and immuno-allergy. Current prescription products include antihistamines, antitussives, a mucolytic and the first nootropic. UCB Pharma is a division of the Belgian-based UCB Group which is comprised of three divisions: pharmaceuticals, chemicals, and flexible films. UCB employs over 8,000 people worldwide. CytoMed, Inc., located in Cambridge, Massachusetts, is a biopharmaceutical company developing novel products for the treatment of inflammatory diseases. The Company has two compounds in clinical development: CMI-977, an orally active product for the treatment of asthma; and CMI-392, for the treatment of inflammatory skin disorders. CytoMed plans to advance these compounds through late-stage development and commercialization by forming partnerships with major pharmaceutical companies. CytoMed currently has development and licensing agreements in place with Steifel Laboratories and Chiron Corporation. Contacts: Richard H. Woodrich Executive Vice President CytoMed, Inc. (617)661-3400 Melinda Lindquist Vice President Feinstein Kean Partners (617) 577-8110